Oral Cancer News – Page 187

Cancer Survivor Gears Up for 25 Mile Bike Ride at the Age of 77

Newark, Ohio — A 77-year-old woman and cancer survivor has biked 25 miles routinely in preparation for this month's Pelotonia bicycle race. Beverly Cote started out biking four miles a day and worked her way up to 25 miles, the distance of Pelotonia, 10TV's Andrea Cambern reported Tuesday. Her inspiration came from someone who made history on a bicycle. "I have been bragging about my grandfather ever since I was a kid," Cote said. Her grandfather, John LaFrance, rode from New York to San Francisco in 22 days and made headlines, Cambern reported. "My grandfather did not have a 10-speed back in 1896," Cote said. "If he could do it, I could do it." He was not the only reason she will ride in the annual bike tour to fight cancer. Cote is a survivor. Over a year ago, she was diagnosed with stage-four throat and tongue cancer. She endured 35 radiation treatments and seven rounds of chemotherapy. "On my last exam with Dr. Old at the James, he said, 'Are you going to ride in Pelotonia, next year?' I told Dr. Old that if he kept me well, for one year, I will ride in it," Cote said. Pelotonia is scheduled to begin on August 19. This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Oral Cancer Foundation News Team - A2011-08-05T12:44:45-07:00August, 2011|Oral Cancer News|

Accuracy of Dentists in the Clinical Diagnosis of Oral Lesions

Source: Quintessence Publishing Objective: Dentists play an important role in the early diagnosis and treatment of oral lesions. However, treatment based solely on a clinical impression of the diagnosis, without histologic confirmation, can result in serious consequences, particularly when the lesion is precancerous or cancerous. The purpose of this study was to determine the overall accuracy of clinical diagnoses made by dentists as well as to compare the diagnostic ability of general practitioners with members of various dental specialties. Method and Materials: The biopsy reports of 976 specimens submitted to the Department of Oral and Maxillofacial Pathology, Virginia Commonwealth University School of Dentistry, between January 2009 and January 2010 were reviewed. The presumptive clinical diagnosis made by the practitioner and the final histologic diagnosis on each specimen were recorded in addition to whether the submitting dentist was a general practitioner or a specialist. Results: Of the clinical diagnoses made by the submitting dentists, 43% were incorrect. General dentists misdiagnosed 45.9%, oral and maxillofacial surgeons 42.8%, endodontists 42.2%, and periodontists 41.2% of the time. The most commonly missed clinical diagnoses were hyperkeratosis (16%), focal inflammatory fibrous hyperplasia (10%), fibroma (8%), periapical granuloma (7%), and radicular cyst (6%). Cancerous lesions were misdiagnosed 5.6% of the time. Conclusions: The high rates of clinical misdiagnosis by dental practitioners indicate that all excised lesions should to be submitted for histologic diagnosis. (Quintessence Int 2011;42:575–577) This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Oral Cancer Foundation News Team - A2011-08-03T09:46:18-07:00August, 2011|Oral Cancer News|

Collaboration of major biomedical centers has shown convergence on a cellular process for head and neck cancers

Source: www.rxpgnews.com Author: Broad Institute of MIT and Harvard Powerful new technologies that zoom in on the connections between human genes and diseases have illuminated the landscape of cancer, singling out changes in tumor DNA that drive the development of certain types of malignancies such as melanoma or ovarian cancer. Now several major biomedical centers have collaborated to shine a light on head and neck squamous cell cancer. Their large-scale analysis has revealed a surprising new set of mutations involved in this understudied disease. In back-to-back papers published online July 28 in Science, researchers from the Broad Institute, Dana-Farber Cancer Institute, Johns Hopkins Kimmel Cancer Center, the University of Pittsburgh, and the University of Texas MD Anderson Cancer Center have confirmed genetic abnormalities previously suspected in head and neck cancer, including defects in the tumor suppressor gene known as p53. But the two teams also found mutations in the NOTCH family of genes, suggesting their role as regulators of an important stage in cell development may be impaired. "This adds a new dimension to head and neck cancer biology that was not on anyone's radar screen before," said Levi A. Garraway, a senior associate member of the Broad Institute, an assistant professor at Dana-Farber Cancer Institute and Harvard Medical School, and a senior author of one of the Science papers. "Head and neck cancer is complex and there are many mutations, but we can infer there is a convergence on a cellular process for which we previously did not have [...]

Oral Cancer Foundation News Team - A2011-08-02T11:40:36-07:00August, 2011|Oral Cancer News|

New Study on Tonsillar Squamous Cell Carcinoma

Source: SAGE Journals Online Objective. To analyze outcomes in patients with squamous cell carcinoma (SCCA) of the tonsil from the years 1998 to 2006. To assess factors that may affect disease-specific survival, such as patient characteristics and/or treatment modality. Study Design and Setting. National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) program. Subjects and Methods. The SEER database was used to perform a population-based cohort analysis for patients diagnosed with SCCA of the tonsil from 1998 to 2006. Disease-specific survival was correlated with sex, age, ethnicity, year of diagnosis, and treatment modality in a univariate Cox proportional hazards analysis and a multiple Cox-regression model with and without interaction effect. Results. Applied inclusion criteria resulted in 8378 patients. Of this patient cohort, 80% were male and 85% were white. The mean patient age at diagnosis was 58.1 years. On univariate and multivariate analyses, ethnicities other than white carried a significantly higher rate of disease-specific death (hazard ratio = 1.71, P

Oral Cancer Foundation News Team - A2011-08-02T10:29:43-07:00August, 2011|Oral Cancer News|

Cigarette Marketing Declined, but Smokeless Tobacco Marketing Doubled in Recent Years

Source: PR Newswire WASHINGTON, Aug. 1, 2011 /PRNewswire-USNewswire/ -- The following is a statement from Matthew L. Myers, President, Campaign for Tobacco-Free Kids: The Federal Trade Commission on Friday reported that cigarette marketing expenditures in the United States declined from $12.5 billion in 2006 to $10.9 billion in 2007 and $9.9 billion in 2008. The FTC also reported that smokeless tobacco marketing increased from $354.1 million in 2006 to $411.3 million in 2007 and $547.9 million in 2008. When measured from 2005, smokeless tobacco marketing has more than doubled (from $250.8 million to $547.9 million). While it is a positive step that cigarette marketing has declined, the tobacco companies continue to spend huge sums to market their deadly and addictive products. Counting both cigarette and smokeless tobacco marketing, the tobacco companies spent $10.5 billion on marketing in 2008 – nearly $29 million each day and 52 percent more than they spent at the time of the 1998 settlement of state lawsuits against the industry, which was supposed to curtail tobacco marketing. Tobacco companies in 2008 spent 20 times more to market tobacco products than the states currently spend on programs to prevent kids from smoking and help smokers quit (the states spent $517.9 million on such programs in fiscal year 2011). This huge mismatch between how much tobacco companies spend to encourage tobacco use and how much states spend to discourage it is a major contributing factor to the slowing of smoking declines in recent years. It is especially troubling [...]

Oral Cancer Foundation News Team - A2011-08-02T09:44:39-07:00August, 2011|Oral Cancer News|

The 3rd congress of the International Academy of Oral Oncology

The meeting on oral oncology was recently held in Singapore. Of the many papers presented there, a couple were of particular interest. The 3rd congress of the International Academy of Oral Oncology was held on July 14—17, 2011, in Singapore. Predicting long term survival in base of tongue cancers The treatment of squamous-cell carcinoma of the tongue-base has evolved from surgery and radiotherapy towards concomitant chemoradiation. Richard Nason (Manitoba, Canada) and colleagues presented results from a historical cohort of 290 patients with advanced cancer of the base of the tongue—followed prospectively—to assess 10-year treatment outcomes over the time that the pattern of treatment was changing. Multivariate models showed an independent effect of stage, sex, age, and initial treatment modality on overall survival. Treatment with radiotherapy and chemotherapy reduced the risk of death over 10 years by 89% (HR 0·11, 95%CI 0·1—0·2; p<0·0001) and surgery plus radiotherapy reduced the risk of death over 10 years by 87% (HR 0·13, 95%CI 0·1—0·2, p<0·0001). Lymph node metastasis gene expressions The assessment and treatment of regional lymph nodes in the neck of patients with squamous-cell carcinoma of the head and neck is the subject of much debate. Frank Leusink (Utrecht, Netherlands) and colleagues presented the validation study of a lymph-node-metastasis gene expression signature to discriminate metastasising from non-metastasising disease. Gene expression was analysed using a DNA microarray that included 696 previously reported predictive genes. The negative predictive value of the signature was assessed on the whole multicentre cohort (n=222), on clinically node negative (cN0) tumours [...]

Oral Cancer Foundation News Team - A2011-08-01T10:40:42-07:00August, 2011|Oral Cancer News|

Secondhand smoke, not just loud music, may harm teens’ hearing

Source: www.modernmedicine.com Author: staff Teenagers may seem to be not listening but they actually may be having trouble hearing. And the reason may not always be their ubiquitous iPod earbuds, especially if they live in a home where someone smokes, new research has suggested. A study in a recent issue of the Archives of Otolaryngology—Head and Neck Surgery recommended that pediatricians consider secondhand smoke exposure to be a risk factor for hearing loss in adolescents and screen accordingly. Approximately 60% of American children are exposed to secondhand smoke, which may also have the potential to have an effect on auditory development, leading to sensorineural hearing loss, according to researchers. Researchers examined the risk factors for sensorineural hearing loss among 1,544 nonsmoking participants aged 12 to 19 years in the 2005-2006 National Health and Nutrition Examination Survey. Adolescents exposed to secondhand smoke had higher rates of low- and high-frequency hearing loss than peers with no secondhand smoke exposure—and the degree of hearing loss increased with the amount of cotinine (a biomarker for nicotine exposure) in the blood. Because most teens do not have routine hearing exams, pediatricians may want to ask follow-up questions of “tuned out” teens, particularly because 82% of those who had hearing loss were unaware of it. Monitoring the hearing of adolescents exposed to secondhand smoke may head off problems in development and functioning associated with early hearing loss.

Oral Cancer Foundation News Team - A2011-07-30T15:34:55-07:00July, 2011|Oral Cancer News|

Introduction of maspin in cancer cell nucleus ‘halts disease’

Source: www.spirehealthcare.com Author: Edward Bartel Scientists in Canada believe the injection of maspin into the nucleus of aggressive cancer cells can dramatically halt the spread of the disease, reducing the chance of needing developed cancer treatment. Studies on two types of aggressive cancer cell, an invasive head and neck cancer and a form of breast cancer, were tested by applying two forms of maspin into the nucleus of one set of cells, while another set was applied to the cytoplasm - the surrounding area of a cell's centre. It has long been assumed that maspin had some effect on the development of cancer. However, the study's findings, published in the Laboratory Investigation journal, suggest that the application of maspin can reduce the instance of cancer metastasis. "Metastasis is the cause of 90 per cent of cancer deaths," said one of the authors of the study, Dr Ann Chambers, professor of oncology, pathology and medical biophysics at Schulich School of Medicine and Dentistry, Canada. She added: "Our new work suggests that when maspin is located in the nucleus it blocks cancer spread and growth." In Britain, Cancer Research UK report that 309,500 people were diagnosed with the disease in 2008, with the possibility of women developing breast cancer now at one in eight. Notes: 1 Goulet, Brigitte, " Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis." Laboratory Investigation. Thursday July 28th 2011. 2 Statistical Information Team: Cancer Research UK, "CancerStats News". May 2011.

Oral Cancer Foundation News Team - A2011-07-30T15:28:34-07:00July, 2011|Oral Cancer News|

Convergence in Head and Neck Cancer

Source: Eurekalert.org Powerful new technologies that zoom in on the connections between human genes and diseases have illuminated the landscape of cancer, singling out changes in tumor DNA that drive the development of certain types of malignancies such as melanoma or ovarian cancer. Now several major biomedical centers have collaborated to shine a light on head and neck squamous cell cancer. Their large-scale analysis has revealed a surprising new set of mutations involved in this understudied disease. In back-to-back papers published online July 28 in Science, researchers from the Broad Institute, Dana-Farber Cancer Institute, Johns Hopkins Kimmel Cancer Center, the University of Pittsburgh, and the University of Texas MD Anderson Cancer Center have confirmed genetic abnormalities previously suspected in head and neck cancer, including defects in the tumor suppressor gene known as p53. But the two teams also found mutations in the NOTCH family of genes, suggesting their role as regulators of an important stage in cell development may be impaired. "This adds a new dimension to head and neck cancer biology that was not on anyone's radar screen before," said Levi A. Garraway, a senior associate member of the Broad Institute, an assistant professor at Dana-Farber Cancer Institute and Harvard Medical School, and a senior author of one of the Science papers. "Head and neck cancer is complex and there are many mutations, but we can infer there is a convergence on a cellular process for which we previously did not have genetic evidence. It shows that if you [...]

Oral Cancer Foundation News Team - A2011-07-28T13:36:56-07:00July, 2011|Oral Cancer News|

Prescription Drug Prices Will Soon Be More Affordable

Source: Stamford Advocate The cost of prescription medicines used by millions of people every day is about to plummet. The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs, including the top two: cholesterol fighter Lipitor and blood thinner Plavix. The magnitude of this wave of expiring drugs patents is unprecedented. Between now and 2016, blockbusters with about $255 billion in global annual sales are set to go off patent, notes EvaluatePharma Ltd., a London research firm. Generic competition will decimate sales of the brand-name drugs and slash the cost to patients and companies that provide health benefits. Top drugs getting generic competition by September 2012 are taken by millions every day: Lipitor alone is taken by about 4.3 million Americans and Plavix by 1.4 million. Generic versions of big-selling drugs for blood pressure, asthma, diabetes, depression, high triglycerides, HIV and bipolar disorder also are coming by then. The flood of generics will continue for the next decade or so, as about 120 brand-name prescription drugs lose market exclusivity, according to prescription benefit manager Medco Health Solutions Inc. "My estimation is at least 15 percent of the population is currently using one of the drugs whose patents will expire in 2011 or 2012," says Joel Owerbach, chief pharmacy officer for Excellus Blue Cross Blue Shield, which serves most of upstate New York. Those patients, along with businesses and taxpayers who help pay for prescription drugs through corporate and government prescription plans, collectively will save [...]

Oral Cancer Foundation News Team - A2011-07-28T10:22:07-07:00July, 2011|Oral Cancer News|